BTIG initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $40 price target vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the analyst tells investors in a research note. The firm expects the company’s lead candidate cadisegliatin, a liver selective glucokinase activator in type 1 diabetes, to reduce hypoglycemic events in the Phase 3 CATT1 trial. It projects over $500M in peak sales for cadisegliatin.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
- vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)
- vTv Therapeutics trading resumes
- vTv Therapeutics trading halted, volatility trading pause
- vTv Therapeutics’ Promising Phase 3 Study on Cadisegliatin for Type 1 Diabetes